Analyzing R&D Budgets: Grifols, S.A. vs Amneal Pharmaceuticals, Inc.

R&D Spending: Grifols vs. Amneal - A Decade of Innovation

__timestampAmneal Pharmaceuticals, Inc.Grifols, S.A.
Wednesday, January 1, 2014106735000180753000
Thursday, January 1, 2015136870000224193000
Friday, January 1, 2016204747000197617000
Sunday, January 1, 2017191938000288320000
Monday, January 1, 2018210451000240661000
Tuesday, January 1, 2019202287000276018000
Wednesday, January 1, 2020190585000294216000
Friday, January 1, 2021209563000354881000
Saturday, January 1, 2022200046000361140000
Sunday, January 1, 2023167778000330551000
Loading chart...

Cracking the code

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Grifols, S.A. and Amneal Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments.

From 2014 to 2023, Grifols, S.A. consistently outpaced Amneal Pharmaceuticals in R&D spending, with an average annual increase of approximately 5%. By 2023, Grifols' R&D budget had surged by 83% from its 2014 levels, peaking at over 330 million. In contrast, Amneal Pharmaceuticals experienced a more modest growth of around 57% over the same period, with its R&D expenses reaching nearly 168 million in 2023.

This divergence highlights Grifols' aggressive pursuit of innovation, while Amneal's steady approach reflects a more conservative strategy. As the pharmaceutical landscape continues to evolve, these investment patterns may shape the future of drug development and healthcare solutions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025